SCHEMBL5136142

SCHEMBL5136142

CCCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCCC)Cc1cc(C)c(O)c(C)c1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
CYP3A4 P08684 4/20 0.40
HPGD P15428 4/20 0.40
HSD17B10 Q99714 4/20 0.40
TSHR P16473 4/20 0.40
CRHR1 P34998 2/20 0.40
HDAC1 Q13547 1/20 0.38
PDE4B Q07343 2/20 0.38
TP53 P04637 1/20 0.38
ATP4A P20648 1/20 0.36
ATP4B P51164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774335 0.97 C5AR1 (0.44) C5AR1ALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5134784 0.95 C5AR1 (0.40) C5AR1ALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5135359 0.92 CRHR1 (0.41) C5AR1ALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5137380 0.92 C5AR1 (0.41) C5AR1ALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5135730 0.92 C5AR1 (0.41) C5AR1TSHRCRHR1
SCHEMBL5074276 0.90 C5AR1 (0.47) C5AR1ALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5136727 0.90 ATP4A (0.40) C5AR1ALDH1A1KDM4EHSD17B10TSHR
SCHEMBL4766543 0.90 C5AR1 (0.45) C5AR1ALDH1A1KDM4ECYP3A4HPGD
SCHEMBL5148382 0.89 CRHR1 (0.41) C5AR1CRHR1HDAC1ATP4AATP4B
SCHEMBL5137962 0.89 C5AR1 (0.44) C5AR1ALDH1A1KDM4ECYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed